Matthew Williams

Matthew Williams

Auto-generated profile, based on publicly available information

Matthew Williams

Cornell University

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2025 in American Journal of Physiology-Endocrinology and Metabolism
Verified
Journal Article
Closed access
CCChloe M. Cheng
Chloe M. Cheng
CBChristopher J. Blay
Christopher J. Blay
PTPei-Yin Tsai
Pei-Yin Tsai
MLMuying Li
Muying Li
MWMatthew Williams
Matthew Williams
JBJoeva Barrow
Joeva Barrow
BAT activation is strongly associated with improved metabolic health such as enhanced cardiometabolic profiles. However, the mechanisms that restrict BAT in this state are unknown. We have identified a putative BAT silencer called AQP1 and through the creation of the first BAT-specific AQP1-KO mouse model, demonstrated that these mice have increased energy expenditure and protection against DIO. Thus, AQP1 is a promising therapeutic target for metabolic dysfunction.

31 July 2025 in American Journal of Physiology-Cell Physiology
Verified
Journal Article
Closed access
YQYue Qu
Yue Qu
KEKaydine Edwards
Kaydine Edwards
MLMuying Li
Muying Li
MWMatthew Williams
Matthew Williams
YLYang Liu
Yang Liu
JBJoeva Barrow
Joeva Barrow
Mitochondrial disease encompasses a group of genetically inherited disorders hallmarked by an inability of the respiratory chain to produce sufficient ATP. These disorders present with multisystemic pathologies that predominantly impact highly energetic tissues such as skeletal muscle. There is no cure or effective treatment for mitochondrial disease. We have discovered a small molecule known as oxybutynin that can bypass Complex III mitochondrial dysfunction in primary murine and human skeletal muscle progenitor cells (MPCs). Oxybutynin administration improves MPC proliferative capacity, enhances cellular glycolytic function, and improves myotube formation. Mechanistically, results from our isothermal shift assay indicates that oxybutynin interacts with a suite of proteins involved in mRNA processing which then trigger the upregulation biological pathways to circumvent CIII mitochondrial dysfunction. Taken together, we provide evidence for the small molecule oxybutynin as a potential therapeutic candidate for the future treatment of CIII mitochondrial dysfunction.